Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 878 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: IFN Clear all

Conditions: Malignancies Including Melanoma, Kidney, Lung, Colorectal, Prostate, Neuroendocrine Tumor
Interventions: rSIFN-co; Biological
Lead sponsor: Sichuan Huiyang Life Science and Technology Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 4
States / cities: Phoenix, Arizona • Chicago, Illinois • Saint Paul, Minnesota

Conditions: Ovarian Carcinoma, Peritoneal Carcinoma
Interventions: Interferon gamma-1b; Drug
Lead sponsor: InterMune; Industry
Eligibility: Female only
Enrollment: 847 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Lymphoma
Interventions: Pegylated interferon α-2b, Psoralens with ultraviolet light A, Narrowband-ultraviolet light B; Biological · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 120 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: IFN-β-1a (Rebif®); Drug
Lead sponsor: Waukesha Memorial Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Waukesha, Wisconsin

Conditions: Myelodysplastic Syndromes, Myeloid Leukemia, Allogeneic Stem Cell Transplantation
Interventions: IFN-γ (interferon gamma-1b) injection; Drug
Lead sponsor: Sawa Ito, MD; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hepatitis C
Interventions: XTL 6865; Drug
Lead sponsor: XTL Biopharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 4
States / cities: Indianapolis, Indiana • New York, New York • Chapel Hill, North Carolina + 1 more

Conditions: Hepatitis, Chronic Active
Interventions: CPG10101, Control; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 14
States / cities: Chicago, Illinois • Indianapolis, Indiana • New Orleans, Louisiana + 11 more

Conditions: Breastcancer, Breast Neoplasm
Interventions: SV-BR-1-GM, Cyclophosphamide, Interferon-alpha-2b; Biological · Drug
Lead sponsor: BriaCell Therapeutics Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Santa Rosa, California • Plantation, Florida • Wichita, Kansas + 2 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Alemtuzumab, Interferon beta-1a; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 581 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 36
States / cities: Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 31 more

Conditions: Pulmonary Disease, Chronic Obstructive, Pulmonary Fibrosis, Cough
Interventions: interferon-alpha lozenges, placebo lozenges; Drug
Lead sponsor: Ainos, Inc. (f/k/a Amarillo Biosciences Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Multiple Myeloma
Interventions: Thalidomide, Ara-C, BCNU, Cisplatin, Cytoxan, Dexamethasone, Doxorubicin, Etoposide, Filgrastim, Recombinant GM-CSF, Interferon-alpha-2b, Melphalan, Vincristine; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 75 Years
Enrollment: 668 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2014
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Hepatitis C
Interventions: Pegylated Interferon, Ribavirin, Liver Biopsy; Drug · Procedure
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Stage IA Skin Melanoma, Stage IB Skin Melanoma, Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
Interventions: recombinant interferon alfa-2b, laboratory biomarker analysis; Biological · Other
Lead sponsor: William Carson; Other
Eligibility: 12 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hepatitis C, Chronic
Interventions: Not listed
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 65
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 53 more

Conditions: Diabetes Mellitus, Type 1
Interventions: interferon alpha; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 3 Years to 25 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hepatitis C, Liver Diseases, Drug Abuse, Alcoholism
Interventions: Pegylated Interferon and Ribavirin, Psychosocial, On-site (MMT Clinic) HCV evaluation and treatment, Off-site HCV evaluation and treatment; Drug · Behavioral
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 2
States / cities: Syracuse, New York

Conditions: Latent Tuberculosis, HIV Infections
Interventions: T-Spot.TB test; Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Staten Island, New York

Conditions: Hepatitis C Virus (HCV)
Interventions: Glecaprevir/pibrentasvir; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 11
States / cities: La Jolla, California • Pasadena, California • Tampa, Florida + 7 more

Conditions: Melanoma
Interventions: melphalan, tumor necrosis factor, interferon-gamma, hyperthermic isolated limb perfusion; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Melanoma (Skin)
Interventions: aldesleukin, filgrastim, recombinant interferon alfa, cisplatin, dacarbazine, vinblastine; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 94
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more

Conditions: Melanoma (Skin)
Interventions: recombinant interferon alfa-2b, azacitidine; Biological · Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 120 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions: cediranib maleate, laboratory biomarker analysis, computed tomography, dynamic contrast-enhanced magnetic resonance imaging, pharmacological study; Drug · Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Colorectal Cancer, Kidney Cancer
Interventions: lymphokine-activated killer cells, recombinant interferon alfa, sargramostim, fluorouracil; Biological · Drug
Lead sponsor: St. Luke's Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: HIV Infections
Interventions: Zidovudine, Interferon gamma-1b; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Study of rSIFN-co for Patients With Advanced Solid Tumors

Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer

Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL

fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls

IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection

CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One

Interferon-alpha Treatment of Chronic Cough in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

Orthotopic Liver Transplant (OLT) Recipients With Hepatitis C Virus (HCV) Under Preemptive Treatment

Recombinant Interferon Alfa-2b in Treating Patients With Melanoma

An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1

Ingested Interferon Alpha: Prolongation or Permanence of the "Honeymoon" Phase in Newly Diagnosed Type 1 Diabetes Mellitus

Improving Hepatitis C Treatment in Injection Drug Users

Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment

A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma

Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma

Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma

AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer

Fluorouracil and Biological Therapy in Treating Patients With Metastatic Kidney or Colorectal Cancer

The Safety and Effectiveness of Injections of Human Recombinant Interferon-gamma in Patients With AIDS Who Have Taken Zidovudine